[Famotidine in the treatment of duodenal peptic ulcer]. / Famotidina en el tratamiento de la úlcera péptica duodenal.
Rev Gastroenterol Peru
; 10(1): 27-32, 1990.
Article
em Es
| MEDLINE
| ID: mdl-2129891
A multicenter, open study was designed to evaluate the efficacy and tolerability of a novel and potent H2 receptor antagonist, Famotidine, in the treatment of duodenal ulcer. Thirty-four patients with endoscopically proven active duodenal ulcer were treated with Famotidine, 40 mg, one tablet, at bedtime, for six weeks. Follow-up endoscopic exams were done every two weeks until ulcer healing was obtained. One patient was excluded from further analysis as he failed to follow the protocol. Healing rates achieved were 48.5%, 91% and 97% by the second, fourth and sixth week of treatment respectively. After 72 hours 52% of the patients were asymptomatic and 79% at the end of the first week of treatment. Famotidine was well tolerated, no clinical neither laboratory adverse events were observed during the study. Famotidine, a novel H2 receptor antagonist appears to be effective and well tolerated in the treatment of most patients with duodenal ulcer.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Famotidina
/
Úlcera Duodenal
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
America do sul
/
Peru
Idioma:
Es
Revista:
Rev Gastroenterol Peru
Assunto da revista:
GASTROENTEROLOGIA
Ano de publicação:
1990
Tipo de documento:
Article
País de publicação:
Peru